RP-3

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameRP-3
Drug Alias NameGenetically modified HSV-1RP-3
ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCell death stimulantsImmunologic cytotoxicityCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors +[5] 
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Tumor necrosis factor ligand superfamily member 4Tumor necrosis factor ligand superfamily member 9
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsBiliary Tract Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesReplimune Inc
China Registration ClassN/A

Develop Information

Active CompaniesReplimune Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursBiliary Tract NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A
Related LinksN/A